tetano
Editor, Senior Moderator
Eur J Clin Microbiol Infect Dis. 2020 Apr 14. doi: 10.1007/s10096-020-03888-7. [Epub ahead of print]
Early combination treatment with baloxavir and peramivir for hospitalized adults with influenza A in Yokohama, Japan.
Yoshimura Y[SUP]1[/SUP], Sasaki H[SUP]2[/SUP], Horiuchi H[SUP]2[/SUP], Miyata N[SUP]2[/SUP], Kawakami C[SUP]3[/SUP], Usuku S[SUP]3[/SUP], Tachikawa N[SUP]2[/SUP].
Author information
Abstract
Baloxavir marboxil is a new anti-influenza drug, but data on the clinical efficacy of a combination treatment of baloxavir and peramivir is scarce. We conducted a single-center retrospective analysis comparing the mortality of a combination of baloxavir and peramivir (B & P, n = 10) and peramivir without baloxavir (P-mono, n = 132) in hospitalized adults with influenza A between 2011 and 2019 in Yokohama City, Japan. Sequencing analysis was conducted in the B & P group to check the I38 mutation in polymerase acidic protein which is associated with baloxavir resistance. The 30-day mortality rates were 0 (0%) in the B & P group and 6 (4.5%) in the P-mono group, respectively, which was not statistically significant. The I38 mutation was not detected before and after the combination treatment. A combination treatment of baloxavir and peramivir might be more effective than peramivir without baloxavir and prevent the emergence of baloxavir resistance in hospitalized adults with influenza A.
KEYWORDS:
Baloxavir; Combination; Influenza; Peramivir
PMID:32291543DOI:10.1007/s10096-020-03888-7
Early combination treatment with baloxavir and peramivir for hospitalized adults with influenza A in Yokohama, Japan.
Yoshimura Y[SUP]1[/SUP], Sasaki H[SUP]2[/SUP], Horiuchi H[SUP]2[/SUP], Miyata N[SUP]2[/SUP], Kawakami C[SUP]3[/SUP], Usuku S[SUP]3[/SUP], Tachikawa N[SUP]2[/SUP].
Author information
Abstract
Baloxavir marboxil is a new anti-influenza drug, but data on the clinical efficacy of a combination treatment of baloxavir and peramivir is scarce. We conducted a single-center retrospective analysis comparing the mortality of a combination of baloxavir and peramivir (B & P, n = 10) and peramivir without baloxavir (P-mono, n = 132) in hospitalized adults with influenza A between 2011 and 2019 in Yokohama City, Japan. Sequencing analysis was conducted in the B & P group to check the I38 mutation in polymerase acidic protein which is associated with baloxavir resistance. The 30-day mortality rates were 0 (0%) in the B & P group and 6 (4.5%) in the P-mono group, respectively, which was not statistically significant. The I38 mutation was not detected before and after the combination treatment. A combination treatment of baloxavir and peramivir might be more effective than peramivir without baloxavir and prevent the emergence of baloxavir resistance in hospitalized adults with influenza A.
KEYWORDS:
Baloxavir; Combination; Influenza; Peramivir
PMID:32291543DOI:10.1007/s10096-020-03888-7